48,834
edits
Difference between revisions of "Cholangiocarcinoma"
Jump to navigation
Jump to search
no edit summary
| Line 9: | Line 9: | ||
| LMDDx = [[metastatic carcinoma]] - esp. luminal GI tract, [[hepatocellular carcinoma]] | | LMDDx = [[metastatic carcinoma]] - esp. luminal GI tract, [[hepatocellular carcinoma]] | ||
| Stains = | | Stains = | ||
| IHC = CK7 +ve, CK20 +ve/-ve, CK19 +ve, HepPar-1 -ve, AFP -ve | | IHC = CK7 +ve, [[CK20]] +ve/-ve, [[CK19]] +ve, HepPar-1 -ve, AFP -ve | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = | ||
| Line 96: | Line 96: | ||
ICC vs. HCC:<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | ICC vs. HCC:<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | ||
*ICC: CK19 (92.5%), MUC-1 (73.8%) +ve. | *ICC: [[CK19]] (92.5%), MUC-1 (73.8%) +ve. | ||
*HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | *HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | ||